Journal
JOURNAL OF VIROLOGY
Volume 87, Issue 13, Pages 7747-7753Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.00327-13
Keywords
-
Categories
Funding
- Burroughs Wellcome Fund
- NIH [R01-AI077955, U01-AI061373, R01-AI089588, U54AI065359]
Ask authors/readers for more resources
Dengue viruses are the most common arthropod-transmitted viral infection, with an estimated 390 million human infections annually and similar to 3.6 billion people at risk. Currently, there are no approved vaccines or therapeutics available to control the global dengue virus disease burden. In this study, we demonstrate the binding, neutralizing activity, and therapeutic capacity of a novel bispecific dual-affinity retargeting molecule (DART) that limits infection of all four serotypes of dengue virus.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
